Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein
Cardiovascular disease is the leading worldwide cause of death. Apolipoprotein E (ApoE) is a 34-kDa circulating glycoprotein, secreted by the liver and macrophages with pleiotropic antiatherogenic functions and hence a candidate to treat hypercholesterolaemia and atherosclerosis. Here, we describe a...
Saved in:
Main Authors: | Ioannis Papaioannou, J. Paul Simons, James S. Owen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/148796 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential therapeutic effects of SIRT1 targeting APOE4-induced microvascular endothelial dysfunction
by: Yorito Hattori, et al.
Published: (2025-03-01) -
Plasma from hypertensive pregnancy patients induce endothelial dysfunction even under atheroprotective shear stress
by: Sarah Viana-Mattioli, et al.
Published: (2025-02-01) -
Correlation between Lpa, APO-A, APO-B, and Stenosis of Middle Cerebral Artery in Patients with Cerebral Ischemic Stroke
by: Xinxu Chen, et al.
Published: (2022-01-01) -
APOEε4 alters ApoE and Fabp7 in frontal cortex white matter in prodromal Alzheimer's disease
by: Marta Moreno-Rodriguez, et al.
Published: (2025-01-01) -
EXISTIRÁ UMA VIDA APÓS O DESENVOLVIMENTO?
by: Serge Latouche
Published: (2014-03-01)